NEW YORK--(BUSINESS WIRE)--Mar. 5, 2019--
UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will
present at two investor conferences in March:
- Cowen and Company 39th Annual Health Care
- Tuesday, March 12th
- 11:20AM Eastern Time
- Boston, MA
- Oppenheimer 29th Annual Healthcare
- Tuesday, March 19th
- 9:10AM Eastern Time
- New York, NY
A live audio webcast of each event will be available on the Investors
section of UroGen's website, www.urogen.com.
A replay of each webcast will be available on the website for
approximately two weeks.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical
company developing advanced non-surgical treatments to address unmet
needs in the field of urology, with a focus on uro-oncology. UroGen has
developed RTGel™, a proprietary sustained release, hydrogel-based
platform technology that has the potential to improve therapeutic
profiles of existing drugs. UroGen’s sustained release technology is
designed to enable longer exposure of the urinary tract tissue to
medications, making local therapy a potentially more effective treatment
option. UroGen’s lead investigational candidates, UGN-101 (mitomycin
gel) for instillation, and UGN-102 (mitomycin gel) for intravesical
instillation, are designed to potentially ablate tumors by non-surgical
means and to treat several forms of non-muscle invasive urothelial
cancer, including low-grade upper tract urothelial cancer and bladder
cancer, respectively. UroGen is headquartered in New York, NY with
operations in Los Angeles, CA and Israel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005221/en/
Source: UroGen Pharma Ltd.
Communications & Investor Relations